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Abstract
The food enzyme is an endo-1,4-b-xylanase (EC 3.2.1.8) produced with a genetically modified strain of
Aspergillus niger (strain XEA), by DSM Food Specialities B.V. The food enzyme is intended to be used in
baking and brewing processes. Based on maximum use levels recommended for the food processes and
individual consumption data from the EFSA Comprehensive European Food Consumption Database,
dietary exposure to the food enzyme–total organic solids (TOS) was estimated to be up to 0.310 mg
TOS/kg body weight per day in European populations. Genotoxicity tests with the food enzyme did not
indicate a genotoxic concern. A repeated dose 90-day oral toxicity study in rodents, carried out with this
endo-1,4-b-xylanase, showed no concern with respect to systemic toxicity. The allergenicity was
evaluated by searching for similarity of the amino acid sequence to those of known allergens; no match
was found. The Panel considers that there are no indications for allergic sensitisation and elicitation
reactions by dietary exposure to the food enzyme endo-1,4-b-xylanase. Based on the microbial source,
the genetic modifications performed, the manufacturing process, the compositional and biochemical data
provided, the dietary exposure assessment, the findings in the toxicological studies and the allergenicity
assessment, the Panel concludes that this food enzyme does not give rise to safety concerns under the
intended conditions of use.
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1. Introduction
Article 3 of the Regulation (EC) No 1332/20081 provides definition for ‘food enzyme’ and ‘food
enzyme preparation’.
‘Food enzyme’ means a product obtained from plants, animals or micro-organisms or products thereof
obtained by a fermentation process using microorganisms: (i) containing one or more enzymes
capable of catalysing a specific biochemical reaction; and (ii) added to food for a technological
purpose at any stage of the manufacturing, processing, preparation, treatment, packaging, transport
or storage of foods.
‘Food enzyme preparation’ means a formulation consisting of one or more food enzymes in which
substances such as food additives and/or other food ingredients are incorporated to facilitate their
storage, sale, standardisation, dilution or dissolution.
Before January 2009, food enzymes other than those used as food additives were not regulated or
were regulated as processing aids under the legislation of the Member States. On 20 January 2009,
Regulation (EC) No 1332/2008 on food enzymes came into force. This Regulation applies to enzymes
that are added to food to perform a technological function in the manufacture, processing,
preparation, treatment, packaging, transport or storage of such food, including enzymes used as
processing aids. Regulation (EC) No 1331/20082 established the European Union (EU) procedures for
the safety assessment and the authorisation procedure of food additives, food enzymes and food
flavourings. The use of a food enzyme shall be authorised only if it is demonstrated that:
• it does not pose a safety concern to the health of the consumer at the level of use proposed,
• there is a reasonable technological need, and
• its use does not mislead the consumer.
All food enzymes currently on the EU market and intended to remain on that market, as well as all
new food enzymes, shall be subjected to a safety evaluation by European Food Safety Authority
(EFSA) and approval via an EU Community list.
The ‘Guidance on submission of a dossier on a food enzyme for evaluation’ (EFSA CEF Panel, 2009)
lays down the administrative, technical and toxicological data required.
1.1. Background and Terms of Reference as provided by the requestor
1.1.1. Background as provided by the European Commission
Only food enzymes included in the European Union (EU) Community list may be placed on the
market as such and used in foods, in accordance with the specifications and conditions of use provided
for in Article 7 (2) of Regulation (EC) No 1332/20081 on food enzymes.
Five applications have been introduced by the Association of Manufacturers and Formulators of
Enzyme Products (AMFEP), and by the companies “DSM Food Specialties B.V” and “Novozymes A/S”
for the authorisation of the food enzymes Pectinase, Poly-galacturonase, Pectin esterase, Pectin lyase
and Arabanase from Aspergillus niger, Phospholipase A2 from a genetically modified strain of
Aspergillus niger (strain PLA), Pectinesterase from a genetically modified strain of Aspergillus niger
(strain PME), Endo-1,4-b-xylanase from a genetically modified strain of Aspergillus niger (strain XEA)
and Maltogenic amylase produced by a genetically modified strain of Bacillus subtilis (strain NZYM-SO)
respectively.
Following the requirements of Article 12.1 of Regulation (EC) No 234/20113 implementing
Regulation (EC) No 1331/20082, the Commission has verified that the five applications fall within the
scope of the food enzyme Regulation and contain all the elements required under Chapter II of that
Regulation.
1 Regulation (EC) No 1332/2008 of the European Parliament and of the Council of 16 December 2008 on Food Enzymes and
Amending Council Directive 83/417/EEC, Council Regulation (EC) No 1493/1999, Directive 2000/13/EC, Council Directive
2001/112/EC and Regulation (EC) No 258/97. OJ L 354, 31.12.2008, p. 7–15.
2 Regulation (EC) No 1331/2008 of the European Parliament and of the Council of 16 December 2008 establishing a common
authorisation procedure for food additives, food enzymes and food flavourings. OJ L 354, 31.12.2008, p. 1–6.
3 Commission Regulation (EU) No 234/2011 of 10 March 2011 implementing Regulation (EC) No 1331/2008 of the European
Parliament and of the Council establishing a common authorisation procedure for food additives, food enzymes and food
flavourings. OJ L 64, 11.3.2011, p. 15–24.
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1.1.2. Terms of Reference
The European Commission requests the European Food Safety Authority to carry out the safety
assessments on the food enzymes Pectinase, Poly-galacturonase, Pectin esterase, Pectin lyase and
Arabanase from Aspergillus niger, Phospholipase A2 from a genetically modified strain of Aspergillus niger
(strain PLA), Pectinesterase from a genetically modified strain of Aspergillus niger (strain PME), Endo-1,4-
b-xylanase from a genetically modified strain of Aspergillus niger (strain XEA) and Maltogenic amylase
produced by a genetically modified strain of Bacillus subtilis (strain NZYM-SO) in accordance with Article
17.3 of Regulation (EC) No 1332/2008 on food enzymes.
1.2. Interpretation of the Terms of Reference
The present scientific opinion addresses the European Commission request to carry out the safety
assessment of the food enzyme endo-1,4-b-xylanase produced with a genetically modified A. niger
(strain XEA).
1.3. Information on existing authorisation and evaluations
The applicant reports that the endo-1,4-b-xylanase activity from A. niger strain XEA has been
evaluated and authorised as a feed additive in the EU, but not for food processing.
2. Data and methodologies
2.1. Data
The applicant has submitted a dossier in support of the application for authorisation of the food
enzyme endo-1,4-b-xylanase produced with a genetically modified A. niger (strain XEA) deposited in
the DSM internal culture collection under accession number DS 38163. The food enzyme is intended to
be used in baking and brewing processes.
2.2. Methodologies
The assessment was conducted in line with the principles described in the EFSA Guidance on
transparency in the scientific aspects of risk assessment (EFSA, 2009) and following the relevant
Guidances from the EFSA Scientific Committee.
The current guidance on the submission of a dossier for safety evaluation of a food enzyme (EFSA CEF
Panel, 2009) has been followed by the CEF Panel for the evaluation of the application with the exception
of the exposure assessment, which was carried out in accordance with the methodology described in the
CEF Panel statement on the exposure assessment of food enzymes (EFSA CEF Panel, 2016).
3. Assessment
3.1. Technical data
3.1.1. Identity of the food enzyme
IUBMB nomenclature: Endo-1,4-b-xylanase
Systematic name: 4-b-D-Xylan xylanohydrolase
Synonyms: Xylanase; b-D-xylanase; endo-1,4-b-D-xylanase




The endo-1,4-b-xylanase food enzyme produced with a genetically modified strain of A. niger XEA
is a single polypeptide of 408 amino acids including a signal peptide of 22 amino acids. The molecular
mass of the mature protein, derived from the amino acid sequence, was calculated to be about
42 kDa. The sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) analysis showed a
prominent band at about 52 kDa and several bands of lower staining intensity.
Safety of endo-1,4-b-xylanase from Aspergillus niger (XEA)
www.efsa.europa.eu/efsajournal 5 EFSA Journal 2018;16(4):5228
Data on the chemical parameters of the food enzyme have been provided for three commercial
food enzyme batches and one batch used for toxicological tests (Table 1).
The average total organic solids (TOS) of the three commercial food enzyme batches was 26.3%
(w/w); the values ranged from 23.7% to 31.1%.
The average enzyme activity/TOS ratio of the three food enzyme batches for commercialisation was
72.5 xylanase activity Units/mg TOS (NXTU/mg TOS); the values ranged from 72.2 to 72.7 NTXU/mg
TOS (Table 1).
The food enzyme complies with the specification for lead (no more than 5 mg/kg) as laid down in
the general specifications and considerations for enzymes used in food processing (FAO/WHO, 2006).
No antimicrobial activity was detected in any of these batches (FAO/WHO, 2006).
The applicant provided data that demonstrate that the concentrations of mycotoxins (fumonisins,
ochratoxin A) of the four food enzyme batches were below the limits of quantification (LOQ) of the
applied analytical methods.4
The food enzyme complies with the microbiological criteria as laid down in the general
specifications and considerations for enzymes used in food processing (FAO/WHO, 2006), which
stipulate that Escherichia coli and Salmonella species are absent in 25 g of sample and total coliforms
should not exceed 30 colony forming units (CFU)/g.
The applicant has provided information on the identity of the antifoam agent used. Taking into
account the nature and properties of the antifoam agent, the manufacturing process and the quality
assurance system implemented by the applicant, the Panel considers its use as of no safety concern.
The Panel considered the compositional data provided for the food enzyme as sufficient.
3.1.3. Properties of the food enzyme
Endo-1,4-b-xylanase catalyses the hydrolysis of 1,4-b-D-xylosidic linkages in xylan (including
arabinoxylan, i.e. xylan branched with arabinose) resulting in the generation of (1?4)-b-D-xylan
oligosaccharides of different chain lengths. The endo-1,4-b-xylanase from A. niger strain XEA does not
require cofactors.
The endo-1,4-b-xylanase activity is quantified based on the hydrolysis of p-nitrophenyl-b-D-
xylopyranoside (pNP-X) to xylose and p-nitrophenol. After adjusting the pH with a sodium carbonate
solution, the yellow colour resulting from p-nitrophenol is determined at 405 nm as a measure of the
enzyme activity. One NTXU is defined as the amount of enzyme that liberates 0.06 lmol p-nitrophenol
per minute under the conditions of the assay (pH 4.5, 37°C).
Endo-1,4-b-xylanase has been characterised regarding its activity depending on temperature and
pH. The temperature profile has been measured from 20°C to 85°C. The xylanase shows a
temperature optimum of 70–80°C (at pH 4.5). The pH profile has been measured from pH range of
3–8, with an optimum of 4.5 (at 37°C). The xylanase is inactivated when heated at 90°C for 15 min.
Table 1: Compositional data of the food enzyme
Parameter Units Batches
1 2 3 4(a)
Xylanase activity NXTU(b)/g 17,200 22,450 17,600 21,185
Protein % 17.7 24.1 18.0 22.2
Ash % 0.7 0.7 0.6 0.4
Water % 75.6 68.2 75.2 70.7
Total organic solids (TOS)(c) % 23.7 31.1 24.2 28.9
Xylanase activity /mg TOS NXTU/mg TOS 72.6 72.2 72.7 73.3
(a): Batch used for the toxicological tests.
(b): NTXU: Xylanase Units (see Section 3.3).
(c): TOS calculated as 100%  % water  % ash
4 LOQ: ochratoxin A: 0.1 µg/kg; fumonisins (B1, B2 and B3): 10 µg/kg each.
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3.1.4. Information on the microbial source material
3.1.4.1. Information related to the genetically modified microorganism
According to the CEF Guidance, the certificate of deposition of the strain in a public validated
culture collection should be provided. The applicant deposited the endo-1,4-b-xylanase production
strain A. niger XEA only in the under number . The
Panel noted that this would not allow a verification of the strain independently of the company.
The production strain XEA has been taxonomically identified
. Moreover, the taxonomic identification is supported by whole
genome sequence (see Section 3.1.4.2).
3.1.4.2. Characteristics of the parental and recipient microorganism
3.1.4.3. Characteristics of the donor organisms
3.1.4.4. Description of the genetic modification process
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3.1.4.5. Safety aspects of the genetic modification
3.1.5. Manufacturing process
The food enzyme is manufactured with food safety procedures based on Hazard Analysis and
Critical Control Points (HACCP), according to the Food Hygiene Regulation (EC) No 852/20045, and in
accordance with current Good Manufacturing Practice (GMP).
The food enzyme is produced by a pure culture in a contained, submerged, fed-batch fermentation
system with conventional process controls in place. The identity and the purity of the culture are
checked at each transfer step from frozen vials until the end of fermentation.
The downstream processing includes recovery, purification and concentration. The food enzyme
produced is recovered from the fermentation broth after killing of mycelium using
and further biomass separation via filtration. Further purification and
concentration involve a series of filtration steps including ultrafiltration, and final polish and germ filtration.
The Panel considered the information provided on the raw materials and manufacturing process as
sufficient.
3.1.6. Safety for the environment
The production strain and its recombinant DNA were not detected in the final product. The
Panel concluded that there is no safety concern for the environment.
3.1.7. Case of need and intended conditions of use
The food enzyme is intended to be used in baking and brewing processes (Table 2).
Table 2: Intended uses and recommended use levels of the food enzyme as provided by the applicant
Food manufacturing process Raw material Recommended use levels (mg TOS/kg RM)
Baking process Flour 0.1–27.6 mg
Brewing process Cereals 0.7–6.9 mg
TOS: total organic solids; RM: raw material.
5 Regulation (EC) No 852/2004 of the European Parliament and of the Council of 29 April 2004 on the hygiene of food additives.
OJ L 226, 25.6.2004, p. 3–21.
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In baking processes, the xylanase food enzyme is added to the raw materials during the
preparation of the dough. It is used to hydrolyse (arabino)xylans, which interact with gluten and bind
water, so contributing to the reduction of dough viscosity. The decrease in dough viscosity facilitates
the handling of the dough, gives improved crumb structure and increases the volume.
In brewing processes, the food enzyme is added during the mashing step. The use of endo-1,4-b-
xylanase results in the reduction of the viscosity of the process streams, which leads to an
improvement of filterability and brewing yield, more flexibility in the choice of raw materials and better
consistency in the quality of the product.
3.1.8. Reaction and fate in food
The enzyme endo-1-4-b-xylanase catalyses the hydrolysis of 1,4-b-D-xylosidic linkages in xylan
resulting in the production of (1?4)-b-D-arabinoxylan oligosaccharides of different lengths. Endo-1,4-
b-xylanase is specific in its action, not known to catalyse other reactions than the endo-hydrolysis of
xylans to shorter xylan chains, xylo-oligosaccharides and xylose. These reaction products are naturally
present in xylan-containing foods. Owing to the substrate specificity of the xylanase, no unintended
reaction products in foods are to be expected.
The data and information provided indicate that the endo-1,4-b-xylanase is inactivated during
processing under the intended conditions of use.
3.2. Dietary exposure
Exposure estimates were calculated using the methodology described in the CEF Panel statement
on the exposure assessment of food enzymes (EFSA CEF Panel, 2016). The assessment of the food
processes covered in this opinion involved selection of relevant food groups and application of process
and technical conversion factors (Appendix B). These input data were subject to a stakeholder
consultation through open calls,6 and adjusted in accordance with feedback received.
3.2.1. EFSA Comprehensive European Food Consumption Database
Since 2010, the EFSA Comprehensive European Food Consumption Database (hereafter the EFSA
Comprehensive Database7) has been populated with detailed national data on food consumption.
Competent authorities in European countries provide EFSA with data regarding the level of food
consumption by individual consumers, as taken from the most recent national dietary survey in their
country (EFSA, 2011a).
The food consumption data gathered by EFSA were collected using different methodologies and
thus direct country-to-country comparisons should be interpreted with caution. Depending on the food
category and the level of detail used in exposure calculations, uncertainties might be introduced owing
to possible subjects’ underreporting and/or misreporting of consumption amounts. Nevertheless, the
EFSA Comprehensive Database is the best available source of food consumption data across Europe.
Food consumption data from the population groups infants, toddlers, children, adolescents, adults
and the elderly were used for the exposure assessment. For the present assessment, food consumption
data were available from 33 different dietary surveys carried out in 19 European countries (Appendix A).
Consumption records were codified according to the FoodEx classification system (EFSA, 2011b).
3.2.2. Exposure assessment methodology
Chronic exposure was calculated based on individual consumption, averaged over the total survey
period, excluding surveys with only one day per subject. High-level exposure/intake was calculated for
only those population groups, in which the sample size was sufficiently large to allow calculation of the
95th percentile (EFSA, 2011a).
The exposure per FoodEx category was subsequently added to derive an individual total exposure per
day. Finally, these exposure estimates were averaged over the number of survey days and normalised for
individual body weight (bw), resulting in an individual average exposure/day per kg bw for the survey
period. This was done for all individuals in the survey and per age class, resulting in distributions of
individual average exposure per survey and age class. Based on these distributions, the mean and 95th
percentile exposures were calculated per survey for the total population and per age class.
6 http://www.efsa.europa.eu/en/data/call/161110
7 http://www.efsa.europa.eu/en/food-consumption/comprehensive-database
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3.2.3. Exposure to food enzyme–TOS according to the intended use proposed by
the applicant
Exposure to the food enzyme–TOS was based on intended use and the recommended maximum
use levels of the food enzyme–TOS provided by the applicant (Section 3.1.7). Food enzyme–TOS
exposure was calculated from foods produced involving a baking process.
Relevant food groups and/or individual foods were selected from the Comprehensive Database and
were assumed to always contain the food enzyme–TOS at the maximum recommended use level. This
will result in an overestimation of exposure to food enzyme–TOS.
To facilitate matching of the reported use levels for baking processes with foods identified in the
Comprehensive Database, the selected foods were disaggregated to ingredient level as appropriate,
and converted into the corresponding raw material, i.e. flour, via the application of conversion factors
(Appendix B). For example, consumption of 100 g of bread was converted into an intake of 70 g flour
(recipe fraction of 0.7) and then multiplied by 27.6 mg TOS/kg flour, as provided by the applicant, to
arrive at an exposure of 1.93 mg TOS/100 g bread.
Exposure to the food enzyme–TOS was calculated by multiplying values reported for each food
category by their respective consumption amount per kilogram of body weight separately for each
individual in the database. Table 3 provides an overview of the derived exposure estimates. The
average and 95th percentile exposure to the food enzyme–TOS per age class, country and survey are
reported in Appendix C – Table 1. The contribution of the food enzyme–TOS from each FoodEx
category to the total dietary exposure is indicated in Appendix C – Table 2.
3.2.4. Uncertainty analysis
In accordance with the guidance provided in the EFSA Opinion related to uncertainties in dietary
exposure assessment (EFSA, 2007), the following sources of uncertainties have been considered and
are summarised in Table 4.
Table 3: Summary of estimated dietary exposure to food enzyme–TOS in six population groups
Estimated exposure (mg/kg body weight per day)
Population
group
Infants Toddlers Children Adolescents Adults The elderly
































TOS: total organic solids.






Consumption data: different methodologies/representativeness/underreporting/
misreporting/no portion size standard
+/–
Use of data from food consumption survey of a few days to estimate long-term
(chronic) exposure for high percentiles (95th percentile)
+
Possible national differences in categorisation and classification of food +/
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The conservative approach applied to the exposure estimate to food enzyme–TOS, in particular,
assumptions made on the occurrence and use levels of this specific food enzyme, is likely to have led
to a considerable over-estimation of the exposure.
3.3. Toxicological data
The test item used for the toxicity studies is described in Table 1 (batch 4). This batch is a
ultrafiltered concentrate, produced according to the procedure used for commercial production.
Despite a lower ash content and a slightly higher specific activity per mg TOS, the Panel considers the
batch 4 as representative for the commercial food enzyme.
3.3.1. Bacterial reverse mutation test
To investigate the potential of the food enzyme to induce gene mutations, a bacterial reverse
mutation assay (Ames test) was performed according to the OECD Test Guideline 471 (OECD, 1997a),
and following Good Laboratory Practice (GLP) in four strains of Salmonella Typhimurium (TA98, TA100,
TA1535, TA1537) and E. coli WP2uvrA pKM 101, in the presence and absence of metabolic activation,
applying the plate incorporation assay. The effect of xylanase activity on S9-mix was tested and it was
observed that the test item did not inhibit the activity of S9-mix. Two independent experiments were
carried out in triplicate using five concentrations of the food enzyme ranging from 50 to 5,000 lg dry
matter/plate of the food enzyme (corresponding to 49–4,932 lg TOS/plate). Appropriate positive
control chemicals and water as a negative control were used. All positive controls induced a significant
increase of revertant colony numbers confirming the sensitivity of the tests and the efficacy of the
metabolic activation; the negative controls were within the historical control ranges. No precipitation or
significant cytotoxicity were observed in any strain at any dose level tested. Upon treatment with the
food enzyme, there was no significant increase in the number of revertant colonies in any tester strain,
both in the presence and absence of metabolic activation. Therefore, the Panel concluded that the
food enzyme did not induce gene mutations in the bacterial reverse mutation assay under the test
conditions employed for this study.
3.3.2. In vitro mammalian chromosome aberration test
The in vitro mammalian chromosome aberration test was carried out according to the OECD Test
Guideline 473 (OECD, 1997b) and following GLP. Chinese hamster ovary cells (CHO) were treated with
the food enzyme, purified water (negative control) or appropriate positive controls both in the absence
and presence of metabolic activation. The effect of xylanase activity on S9-mix was tested and it was
observed that the test item did not inhibit the activity of S9-mix. Based on the results obtained in a
dose-range finding test, the cells were treated with 1,250, 2,500 and 5,000 lg dry matter/mL
(corresponding to 1,233, 2,466 and 4,932 lg TOS/mL) applying a short-term treatment (3 + 17 h of
recovery) in the presence and absence of S9-mix, and with 750, 3,000 and 5,000 lg dry matter/mL
(corresponding to 740, 2,959 and 4,932 lg TOS/mL) applying a continuous treatment (20 + 0 h) in





Model assumptions and factors
FoodEx categories included in the exposure assessment were assumed to always
contain the food enzyme–TOS
+
Exposure to food enzyme–TOS was always calculated based on the recommended
maximum use level
+
Selection of broad FoodEx categories for the exposure assessment +
Use of recipe fractions in disaggregation FoodEx categories likely to contain the food
enzyme
+/
Use of technical factors in the exposure model +/
TOS: total organic solids.
+: uncertainty with potential to cause over-estimation of exposure; –: uncertainty with potential to cause underestimation of
exposure.
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metaphases were scored per experimental point. The positive controls induced statistically significant
increases in chromosomal aberration frequency and the system was considered sensitive and valid.
The negative controls were within the historical vehicle control ranges. Cytotoxicity, measured as
mitotic inhibition, did not exceed 23% of concurrent negative control values at any concentration of
the food enzyme. No statistically significant increase in the frequency of chromosomal aberrations was
observed in the short term treated cultures compared to the negative controls both in the presence
and absence of metabolic activation. After continuous treatment in the absence of S9-mix, a
statistically significant increase in the frequency of aberrant cells was observed only at 5,000 lg dry
matter/mL (0 vs 2.5% aberrant cells at 0 and 5,000 lg dry matter/mL, respectively). However, the
increase was slightly above the historical negative control range (0–2) that was not considered robust
because it was based only on six experiments. Therefore, the increase was not considered biological
relevant and the Panel concluded that the food enzyme did not induce chromosomal aberrations under
the experimental conditions employed for this study.
3.3.3. Repeated Dose 90-day Oral Toxicity Study in Rodents
A repeated dose 90-day oral toxicity study in rodents was performed according to OECD test
guideline 408 (OECD, 1998) and following GLP. Groups of ten male and ten female Wistar rats received
daily via gavage for at least 90 days dose levels of 0 (double distilled water as vehicle), 400, 1,600 and
6,400 mg food enzyme/kg bw per day in a volume of 10 mL/kg bw per day, corresponding to 0, 116,
463 and 1,852 mg TOS/kg bw per day (referred to as control, low-, mid- and high dose groups).
No treatment-related deaths or effects on clinical signs, body weight and body weight gains, food
consumption, ophthalmoscopic examinations, organ weights and organ weight ratios, and macroscopic
or microscopic pathology were observed.
In the functional observation battery tests a lower grip strength value was observed in forelimbs of
males in the low-dose group and a higher grip strength value in hindlimbs of the mid-dose group. In
females a significantly higher grip strength value was observed in forelimbs of the mid- and high-dose
groups and in hindlimbs of the high-dose group. All these changes were considered to be incidental
findings since they lacked dose relationship. Significantly higher values of landing foot splay were
observed in mid and high dose males and females and were also considered to be incidental, as there
was no change in gait observed in these animals.
In haematology evaluation significant incidental increases were observed in mid-dose males for
mean corpuscular haemoglobin (MCH), mean corpuscular haemoglobin concentration (MCHC) (also in
high dose males), platelets, prothrombin time, neutrophils and decreased values for lymphocytes. The
higher levels of MCHC in mid- and high-dose males were considered incidental, as the corresponding
changes were not observed in red blood cell counts and haemoglobin. In females, a significantly
increased mean corpuscular volume (MCV) was seen in low- and mid-dose animals, a higher level of
haematocrit in mid-dose females, and an increased neutrophil percentage with lower lymphocyte
percentage in high-dose females. These changes were minor and were considered as incidental and
attributed to normal biological variation.
In clinical chemistry evaluation some parameters were only affected in males. Minor increased
sodium and chloride levels were observed in the high dose group which were considered to be
attributed to normal biological variation. The dose-related increased creatinine levels at mid- and high-
doses groups were considered as incidental, as there was no corresponding histopathological changes
in the kidneys.
The Panel derived a no observed adverse effect level (NOAEL) based on the high-dose level of this
repeated dose 90-day oral toxicity study of 1,852 mg TOS/kg bw per day.
A comparison of the NOAEL (1,852 mg TOS/kg bw per day) from the 90-day study with the derived
exposure estimates of 0.019–0.174 mg/kg bw per day at the mean and from 0.064–0.310 mg TOS/ kg
bw per day at the 95th percentile, resulted in margins of exposure (MOEs) above 5,974, indicating
that there is no safety concern.
3.4. Allergenicity
The allergenicity assessment considers only the food enzyme and not any carrier or other excipient
which may be used in the final formulation.
The potential allergenicity of the endo-1,4-b-xylanase produced with the genetically modified
A. niger strain XEA was assessed by comparing its amino acid sequence with those of known allergens
according to the scientific opinion on the assessment of allergenicity of genetically modified plants and
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microorganisms and derived food and feed of the Scientific Panel on Genetically Modified Organisms
(EFSA GMO Panel, 2010). Using higher than 35% identity in a sliding window of 80 amino acids as the
criterion, no match was found.
Endo-1,4-b-xylanase from A. niger strain XEA is not listed as an allergen in the AllergenOnline8 and the
WHO/IUIS Allergen Nomenclature9 database. No information is available on oral sensitisation and
elicitation reactions of this endo-1,4-b-xylanase. Several cases of respiratory allergy following occupational
inhalation of xylanase have been reported (Elms et al., 2003; Martel et al., 2010). However, some studies
have shown that adults with occupational asthma to an enzyme used in food can commonly ingest the
corresponding allergen without acquiring clinical symptoms of food allergy (Cullinan et al., 1997; Brisman,
2002; Poulsen, 2004; Armentia et al., 2009). In addition, only incidental cases have been described where
ingestion of a-amylase led to adverse reaction in patients sensitised through the respiratory route (Baur
and Czuppon, 1995; Kanny and Moneret-Vautrin, 1995; Moreno-Ancillo et al., 2004). Such information on
adverse reactions upon ingestion of endo-1,4-b-xylanase in individuals sensitised through the respiratory
route has not been reported. Therefore, it can be concluded that an allergic reaction upon oral ingestion of
endo-1,4-b-xylanase produced with the genetically modified A. niger strain XEA, in individuals respiratory
sensitised to xylanase cannot be excluded, but the likelihood of such reaction to occur is considered to be
low.
The potential cross reactivity of food enzymes was studied by Bindslev-Jensen et al. (2006). There
were no indications of cross reactivity between 19 different commercial food enzymes and the main
allergens represented by 400 patients (allergic to inhalation allergens, food allergens, allergens of bee or
wasp or drugs) included in this study. As no individuals were reported to be allergic to food enzymes, no
conclusion can be drawn regarding the potential allergenicity of endo-1,4-b-xylanase from A. niger.
Taken together, the Panel considers that under the intended condition of use there are no indications
for allergic sensitisation and elicitation reactions by dietary exposure to the food enzyme endo-1,4-b-
xylanase produced with the genetically modified A. niger strain XEA.
4. Conclusions
Based on the genetic modifications performed, the manufacturing process, the compositional and
biochemical data provided, the dietary exposure assessment, the findings in the toxicological studies
and the allergenicity assessment, the Panel concludes that the food enzyme endo-1,4-b-xylanase from
Aspergillus niger strain XEA does not give rise to safety concerns under the intended conditions of use.
Documentation provided to EFSA
1) Dossier “Application for authorisation of endo-1,4-ß-xylanase from a genetically modified
strain of Aspergillus niger XEA”. First submission data by January 2015. Submitted by DSM
Food Specialties. Second submission data by September 2015.
2) Preparatory work reports on technical data, toxicological data and on the genetic
modifications were delivered by FoBiG GmbH (Freiburg, Germany) on 22 August 2016 and by
the Technical University of Denmark (Søborg, Denmark) on 1 March 2016, respectively.
3) Additional information received from DSM Food Specialities B.V. in January 2018.
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Abbreviations
AMFEP Association of Manufacturers and Formulators of Enzyme Products
bw body weight
CAS Chemical Abstracts Service
CFU colony forming units
CHO Chinese hamster ovary cells
EC European Commission and Enzyme Commission
EINECS European Inventory of Existing Commercial Chemical Substances
FAO Food and Agricultural Organization
GLP Good Laboratory Practice
GMP Good Manufacturing Practice
HACCP Hazard Analysis and Critical Control Points
IUBMB International Union of Biochemistry and Molecular Biology
LOQ limit of quantification
MCH mean corpuscular haemoglobin
MCHC mean corpuscular haemoglobin concentration
MCV mean corpuscular volume
MOE Margin of Exposure
NOAEL no observed adverse effect level
NXTU Xylanase Unit
OECD Organisation for Economic Cooperation and Development
PCR polymerase chain reaction
pNP-X p-nitrophenyl-b-D-xylopyranoside
QPS Qualified Presumption of Safety
RM raw material
SDS–PAGE sodium dodecyl sulfate–polyacrylamide gel electrophoresis
TOS total organic solids
WHO World Health Organization
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Appendix A – Population groups considered for the exposure assessment
Population Age range
Countries with food consumption surveys covering more
than one day
Infants From 12 weeks on up to and
including 11 months of age
Bulgaria, Denmark, Finland, Germany, Italy, United Kingdom
Toddlers From 12 months up to and
including 35 months of age
Belgium, Bulgaria, Denmark, Finland, Germany, Italy,
Netherlands, Spain, United Kingdom
Children(a) From 36 months up to and
including 9 years of age
Austria, Belgium, Bulgaria, Czech Republic, Denmark, Finland,
France, Germany, Greece, Italy, Latvia, Netherlands, Spain,
Sweden, United Kingdom
Adolescents From 10 years up to and
including 17 years of age
Austria, Belgium, Cyprus, Czech Republic, Denmark, Finland,
France, Germany, Italy, Latvia, Spain, Sweden, United Kingdom
Adults From 18 years up to and
including 64 years of age
Austria, Belgium, Czech Republic, Denmark, Finland, France,
Germany, Hungary, Ireland, Italy, Latvia, Netherlands, Romania,
Spain, Sweden, United Kingdom
The elderly(a) From 65 years of age
and older
Austria, Belgium, Denmark, Finland, France, Germany, Hungary,
Ireland, Italy, Romania, Sweden, United Kingdom
(a): The terms ‘children’ and ‘the elderly’ correspond, respectively, to ‘other children’ and the merge of ‘elderly’ and ‘very elderly’
in the Guidance of EFSA on the ‘Use of the EFSA Comprehensive European Food Consumption Database in Exposure
Assessment’ (EFSA, 2011a).
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Appendix B – FoodEx categories used to derive exposure estimates for the
food enzyme–TOS and the respective conversion factors
FoodEx code FoodEx category
Conversion factor from







A.01 Grains and grain-based products
(unspecified)
0.8 1 27.6
A.01.03 Grain milling products (unspecified) 1 1 27.6
A.01.03.001 Wheat milling products (unspecified) 1 1 27.6
A.01.03.001.001 Wheat flour, brown 1 1 27.6
A.01.03.001.002 Wheat flour, Durum 1 1 27.6
A.01.03.001.003 Wheat flour, white 1 1 27.6
A.01.03.001.004 Wheat flour, wholemeal 1 1 27.6
A.01.03.001.005 Graham flour 1 1 27.6
A.01.03.001.006 Wheat flour, gluten free 1 1 27.6
A.01.03.001.014 Wheat starch 1.2 1 27.6
A.01.03.002 Rye milling products (unspecified) 1 1 27.6
A.01.03.002.001 Rye flour, gluten free 1 1 27.6
A.01.03.002.002 Rye flour, light 1 1 27.6
A.01.03.002.003 Rye flour, medium 1 1 27.6
A.01.03.002.004 Rye flour, wholemeal 1 1 27.6
A.01.03.003 Buckwheat milling products
(unspecified)
1 1 27.6
A.01.03.003.001 Buckwheat flour 1 1 27.6
A.01.03.004 Corn milling products (unspecified) 1 1 27.6
A.01.03.004.001 Corn flour 1 1 27.6
A.01.03.004.003 Corn starch 1.3 1 27.6
A.01.03.005 Oat milling products (unspecified) 1 1 27.6
A.01.03.005.002 Oat flour 1 1 27.6
A.01.03.005.004 Oat starch 1.2 1 27.6
A.01.03.006 Rice milling products (unspecified) 1 1 27.6
A.01.03.006.001 Rice flour 1 1 27.6
A.01.03.006.002 Rice flour white 1 1 27.6
A.01.03.006.003 Rice flour, instant 1 1 27.6
A.01.03.006.004 Rice starch 1.2 1 27.6
A.01.03.007 Spelt milling products 1 1 27.6
A.01.03.008 Other milling products (unspecified) 1 1 27.6
A.01.03.008.001 Amaranth flour 1 1 27.6
A.01.03.008.002 Barley flour 1 1 27.6
A.01.03.008.003 Chapatti flour 1 1 27.6
A.01.03.008.004 Flour mix, wheat/rye/barley/oats 1 1 27.6
A.01.03.008.005 Millet flour 1 1 27.6
A.01.03.008.007 Sorghum flour 1 1 27.6
A.01.04 Bread and rolls (unspecified) 1 0.7 27.6
A.01.04.001 Wheat bread and rolls 1 0.7 27.6
A.01.04.002 Rye bread and rolls 1 0.7 27.6
A.01.04.003 Mixed wheat and rye bread and rolls 1 0.7 27.6
A.01.04.004 Multigrain bread and rolls 1 0.7 27.6
A.01.04.005 Unleavened bread, crisp bread and
rusk (unspecified)
1 0.8 27.6
A.01.04.005.001 Crisp bread, rye wholemeal 1 0.9 27.6
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FoodEx code FoodEx category
Conversion factor from







A.01.04.005.002 Crisp bread, rye, light 1 0.9 27.6
A.01.04.005.003 Crisp bread, wheat, wholemeal 1 0.9 27.6
A.01.04.005.004 Crisp bread, wheat, light 1 0.9 27.6
A.01.04.005.005 Rusk, light 1 0.9 27.6
A.01.04.005.006 Rusk, wholemeal 1 0.9 27.6
A.01.04.005.007 Pita bread 1 0.7 27.6
A.01.04.005.008 Matzo 1 0.9 27.6
A.01.04.005.009 Tortilla 1 0.7 27.6
A.01.04.006 Other bread 1 0.7 27.6
A.01.04.007 Bread products 1 0.7 27.6
A.01.07 Fine bakery wares (unspecified) 1 0.5 27.6
A.01.07.001 Pastries and cakes (unspecified) 1 0.5 27.6
A.01.07.001.001 Beignets 1 0.15 27.6
A.01.07.001.002 Buns 1 0.7 27.6
A.01.07.001.003 Cake from batter 1 0.25 27.6
A.01.07.001.004 Cheese cream cake 1 0.24 27.6
A.01.07.001.005 Cheese cream sponge cake 1 0.24 27.6
A.01.07.001.006 Chocolate cake 1 0.24 27.6
A.01.07.001.007 Chocolate cake with fruits 1 0.24 27.6
A.01.07.001.008 Cream cake 1 0.24 27.6
A.01.07.001.009 Cream cheese cake 1 0.24 27.6
A.01.07.001.010 Cream custard cake 1 0.24 27.6
A.01.07.001.011 Cream custard sponge cake 1 0.24 27.6
A.01.07.001.012 Croissant 1 0.5 27.6
A.01.07.001.013 Croissant, filled with chocolate 1 0.5 27.6
A.01.07.001.014 Croissant, filled with cream 1 0.5 27.6
A.01.07.001.015 Croissant, filled with jam 1 0.5 27.6
A.01.07.001.016 Croquembouche 1 0.15 27.6
A.01.07.001.017 Doughnuts 1 0.24 27.6
A.01.07.001.018 Clair 1 0.15 27.6
A.01.07.001.019 Flan 1 0.5 27.6
A.01.07.001.020 Fruit cake 1 0.6 27.6
A.01.07.001.021 Fruit pie 1 0.15 27.6
A.01.07.001.022 Cheese pie 1 0.15 27.6
A.01.07.001.023 Fruit tart 1 0.15 27.6
A.01.07.001.024 Gingerbread 1 0.6 27.6
A.01.07.001.025 Gougere 1 0.15 27.6
A.01.07.001.026 Kringles 1 0.25 27.6
A.01.07.001.027 Nut cream cake 1 0.24 27.6
A.01.07.001.028 Pancakes 1 0.25 27.6
A.01.07.001.029 Profiterole 1 0.15 27.6
A.01.07.001.030 Pyramid cake 1 0.25 27.6
A.01.07.001.031 Rhubarb flan 1 0.15 27.6
A.01.07.001.032 Scone 1 0.5 27.6
A.01.07.001.033 Sponge dough 1 0.25 27.6
A.01.07.001.034 Sponge cake 1 0.25 27.6
A.01.07.001.035 Sponge cake roll 1 0.25 27.6
A.01.07.001.036 Muffins 1 0.25 27.6
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FoodEx code FoodEx category
Conversion factor from







A.01.07.001.037 Waffles 1 0.25 27.6
A.01.07.001.038 Apple strudel 1 0.15 27.6
A.01.07.001.039 Cream-cheese strudel 1 0.24 27.6
A.01.07.001.040 Cheese pastry goods from puff pastry 1 0.15 27.6
A.01.07.001.041 Croissant from puff pastry 1 0.6 27.6
A.01.07.001.042 Brioche 1 0.5 27.6
A.01.07.001.044 Lebkuchen 1 0.6 27.6
A.01.07.001.045 Dumpling 1 0.5 27.6
A.01.07.001.046 Cake marbled, with chocolate 1 0.5 27.6
A.01.07.001.047 Marzipan pie 1 0.25 27.6
A.01.07.001.048 Baklava 1 0.15 27.6
A.01.07.002 Biscuits (cookies) 1 0.9 27.6
A.01.07.002.001 Biscuits, sweet, plain 1 0.9 27.6
A.01.07.002.002 Biscuits, chocolate filling 1 0.81 27.6
A.01.07.002.003 Biscuits, cream filling 1 0.81 27.6
A.01.07.002.004 Biscuits, fruit filling 1 0.81 27.6
A.01.07.002.005 Biscuits, vanilla filling 1 0.81 27.6
A.01.07.002.006 Butter biscuits 1 0.81 27.6
A.01.07.002.007 Biscuit, iced 1 0.81 27.6
A.01.07.002.008 Speculaas 1 0.9 27.6
A.01.07.002.009 Biscuits, sweet, wheat wholemeal 1 0.9 27.6
A.01.07.002.010 Biscuits, oat meal 1 0.9 27.6
A.01.07.002.011 Biscuits, spelt meal 1 0.9 27.6
A.01.07.002.012 Biscuits, salty 1 0.9 27.6
A.01.07.002.013 Biscuits, salty, with cheese 1 0.81 27.6
A.01.07.002.014 Sticks, salty 1 0.81 27.6
A.17.03.003 Biscuits, rusks and cookies for
children
1 0.9 27.6
A.18.04.001 Find bakery products for diabetics 1 0.5 27.6
A.19.01.001 Sandwich and sandwich-like meal 1 0.32 27.6
A.19.01.002 Pizza and pizza-like pies 1 0.3 27.6
A14.01 Beer and beer-like beverage 1.37 0.19 6.9
A.14.01.001 Beer, strong 1.37 0.265 6.9
A.14.01.002 Beer, regular 1.37 0.19 6.9
A.14.01.003 Beer, light (reduced alcohol content) 1.37 0.135 6.9
A.14.01.004 Beer, alcohol-free 1.37 0.135 6.9
A.14.01.005 Beer-like beverages (malt drink) 1.37 0.19 6.9
TOS: total organic solids.
(a): Available at see http://wwwfaoorg/fileadmin/templates/ess/documents/methodology/tcfpdf
(b): Derived from publically available recipe information, and/or food label information (such as the Mintel’s Global New Products
Database http://wwwmintelcom/global-new-products-database).
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Appendix C – Dietary exposure estimates to the food enzyme–TOS in
details
Information provided in this appendix is shown in an excel file (downloadable http://onlinelibrary.
wiley.com/wol1/doi/10.2903/j.efsa.2018.5228/suppinfo).
The file contains two sheets, corresponding to two tables.
Table 1: Average and 95th percentile exposure to the food enzyme–TOS per age class, country
and survey
Table 2: The contribution of the food enzyme–TOS from each FoodEx category to the total dietary
exposure
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